CDT

NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 20, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today notes the announcement from Sarborg Limited regarding the filing of a new patent application covering a large set of field-deployable, two-component combination interventions for sugarcane cultivation, generated through Sarborg's quantum-enabled PRISM platform. According to Sarborg, the filing organizes its claimed combinations around six distinct application configurations, each defined by the growth stage of application, the delivery route, the dose and timing, and the agronomic target addressed. Within this framework, Sarborg has identified 606 fiel

8-K - CDT Equity Inc. (0001896212) (Filer)

NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 16, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), announces that its board of directors has approved a 1-for-10 reverse stock split of the Company’s common stock, to ensure continued compliance with the Nasdaq bid-price rule. The Company’s stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios. The reverse stock split will become effective on July 17, 2026, at 5:00 pm, Eastern Time (the "Effective Time"), and the Company’s common stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasd

10-Q - CDT Equity Inc. (0001896212) (Filer)

8-K - CDT Equity Inc. (0001896212) (Filer)

8-K - CDT Equity Inc. (0001896212) (Filer)

NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 26, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today notes the announcement from Sarborg Limited regarding the expansion of its Signature Intelligence platform into quantum-assisted coformer selection through SarborgQ, the Company's dedicated quantum computing division. According to Sarborg, the initiative combines the Company's proprietary datasets, agentic AI architecture and emerging quantum computing capabilities to support coformer selection across its owned intellectual property portfolio and future client engagements. Sarborg has curated a proprietary database of more than 850 coformers and is dev

4 - CDT Equity Inc. (0001896212) (Issuer)

NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 18, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today notes the announcement from Sarborg Limited regarding its recent fundraise from a New York-based private investment fund. According to Sarborg, the subscription was completed at a consideration per share of $125,000, implying a fully diluted valuation of approximately $638.3 million. The proceeds will be used to support the launch and development of SarborgQ, Sarborg's newly formed quantum computing division, alongside continued expansion of the Company's proprietary datasets, acceleration of intellectual property generation, support of asset developme

8-K - CDT Equity Inc. (0001896212) (Filer)

NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 16, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced that it has re-structured its debt, agreeing to pay off all outstanding amounts due under its Loan Notes with Alliance Global Partners ("A.G.P.") and Ascent Partners, and entering into a new Loan Agreement with JJ Astor for up to $1,460,000. The A.G.P. Convertible Loan Note originally entered into in December 2024, had a principal amount of $5,737,500, which was repaid in full as of the beginning of June. In addition, the Company will repay $555,555.56 (exclusive of interest), pursuant to the Promissory Note with Ascent Partners entered int

8-K - CDT Equity Inc. (0001896212) (Filer)

NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 28, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced that the Company received a written notice ("Notice") from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on May 21, 2026 indicating that the Company did not timely file its Quarterly Report on Form 10-Q for the three-month period ended March 31, 2026 (the "Form 10-Q"), as required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5250(c)(1) (the "Periodic Filing Requirement"). The Notice does not have an immediate effect on the listing or trading of the Company's securiti

NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 27, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announces that the patent covering the use of AZD5904 in male infertility has now been granted in Canada, completing the approval of this patent in all key pharmaceutical target markets. CDT believes that the extensive geographical coverage of this patent combined with its more recent composition of matter application provides a strong IP position for development of AZD5904 in male infertility as discussions continue regarding potential licensing and strategic partnering opportunities. Originally licensed from AstraZeneca, AZD5904 benefits from an exte

NT 10-Q - CDT Equity Inc. (0001896212) (Filer)

8-K - CDT Equity Inc. (0001896212) (Filer)

4 - CDT Equity Inc. (0001896212) (Issuer)

NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 07, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today notes the announcement from Sarborg Limited regarding the filing of a new Substance of Matter (SOM) patent covering two established compounds within the cystic fibrosis market. Sarborg announced that the patent was developed using its proprietary Signature Agent and Multi-Agent platform, supported by its Sarborg 1,600 Disease Database and Sarborg 1,700 Rare Disease Database. According to Sarborg, this approach enables rapid identification of new therapeutic opportunities, including additional indications and combination strategies, with patent filing

NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 06, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announces that AZD5904, a potent inhibitor of human Myeloperoxidase, originally licensed from AstraZeneca, has progressed into the Patent Cooperation Treaty ("PCT") phase, marking a significant step in the globalisation of its intellectual property (IP) protection. AZD5904 benefits from an extensive clinical safety data package, with a total of 181 subjects dosed across five Phase 1 studies. The asset has demonstrated a favourable safety profile, with no overtly drug-related adverse events identified. The Company believes this level of human clinical va

EFFECT - CDT Equity Inc. (0001896212) (Filer)

424B3 - CDT Equity Inc. (0001896212) (Filer)

3 - CDT Equity Inc. (0001896212) (Issuer)

8-K - CDT Equity Inc. (0001896212) (Filer)

S-3 - CDT Equity Inc. (0001896212) (Filer)

NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 16, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today provides a strategic update outlining its positioning as a multi-pathway value creation business spanning a pharmaceutical asset portfolio, proprietary solid-form intellectual property and artificial intelligence-driven indication discovery. The Company believes it is uniquely positioned through a combination of high-quality clinical assets, proprietary chemistry, and advanced data-driven capabilities to generate long-term shareholder value through a capital-efficient, out-licensing model. CDT continues to evaluate and advance its portfolio of asse